Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by CPAP: Randomised phase 3 study.

Autor: Dauvilliers Y; Centre National de Référence Narcolepsie, Unité du Sommeil, CHU Montpellier, Hôpital Gui-de-Chauliac, Service de Neurologie, Université de Montpellier, INSERM INM, Montpellier, France., Craig SE; Liverpool Sleep and Ventilation Centre, University Hospital Aintree, Liverpool University Foundation Trust, Liverpool, UK., Bonsignore MR; PROMISE Department, University of Palermo, Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), Palermo, Italy., Barbé F; Respiratory Department, Institut Ricerca Biomedica de Vilanova, Lleida, Spain., Verbraecken J; Multidisciplinary Sleep Disorders Centre, Antwerp University Hospital and University of Antwerp, Edegem-Antwerp, Belgium., Asin J; Department of Pulmonary Medicine, Centre for Sleep Medicine, Amphia Hospital, Breda, The Netherlands., Georgiev O; Department of Internal Medicine, Pulmonology, Alexandrovska Hospital Medical University, Sofia, Bulgaria., Tiholov R; Department of Internal Diseases, Sv. Ivan Rilski Multiprofile Hospital for Active Treatment, Kozloduy, Bulgaria., Caussé C; Bioprojet Pharma, Paris, France., Lecomte JM; Bioprojet Pharma, Paris, France., Schwartz JC; Bioprojet Pharma, Paris, France., Lehert P; Faculty of Economics, University Louvain, Ottignies-Louvain-la-Neuve, Belgium.; Faculty of Medicine, University of Melbourne, Melbourne, Victoria, Australia., Randerath W; Bethanien Hospital, Institute of Pneumonology, University of Cologne, Solingen, Germany., Pépin JL; HP2 Laboratory INSERM U1300, University Grenoble Alpes, Grenoble, France.
Jazyk: angličtina
Zdroj: Journal of sleep research [J Sleep Res] 2024 Oct 08, pp. e14373. Date of Electronic Publication: 2024 Oct 08.
DOI: 10.1111/jsr.14373
Abstrakt: Obstructive sleep apnea (OSA) syndrome commonly leads to excessive daytime sleepiness (EDS). Pitolisant, a selective histamine-3 receptor antagonist, is efficacious at doses up to 20 mg once daily in OSA treated or not with continuous positive airway pressure (CPAP). We assessed the efficacy and safety of pitolisant at doses up to 40 mg once daily in patients with moderate to severe OSA treated or not with CPAP therapy. In this phase 3, multicentre, randomised, double-blind, placebo-controlled clinical trial, patients with OSA were assigned 2:1 to receive pitolisant (according to an individual up-titration scheme, 10, 20 or 40 mg once daily) or placebo for 12 weeks. The primary endpoint was a change in the Epworth Sleepiness Scale (ESS) score from baseline to week 12. Secondary endpoints included a change in reaction time using the Oxford Sleep Resistance test (OSleR), Clinical Global Impression of Change (CGI-C), and Patient's Global Opinion of the Effect (PGOE) of study treatment. Overall, 361 patients (mean age 52.4 years, 77.3% male; mean apnea-hypopnea index [AHI] 27.0 events/h) were randomised to receive pitolisant (n = 242; 50% received CPAP) or placebo (n = 119; 48.7% CPAP). After the dose-adjustment phase (week 3), 88.8% of patients received pitolisant 40 mg. Compared with placebo, pitolisant produced a significant reduction in the ESS score at week 12 (least square mean difference -2.6 (95% CI: -3.4; -1.8; p < 0.001)) irrespective of CPAP use; and improved the reaction time on OSleR, CGI-C, and PGOE at week 12. Pitolisant was well tolerated; no new safety signals were identified. In conclusion, pitolisant up to 40 mg once daily was an effective treatment for EDS in patients with moderate to severe OSA irrespective of CPAP use.
(© 2024 The Author(s). Journal of Sleep Research published by John Wiley & Sons Ltd on behalf of European Sleep Research Society.)
Databáze: MEDLINE
Externí odkaz: